Saturday, 22 December 2012

OncoMed initiates Phase 1 clinical trial on an antibody that kills cancer stem cells

OncoMed Pharmaceuticals announced today, that it will soon start Phase 1 human clinical trials on the OMP-52M51 product they have been developing. OMP-52M51 is an artificial monoclonan antibody that targets cancer stem cells (CSCs).

During the first phase of the clinical trial, the antibody will be administered to patients with hematologic cancers. It will be tested for safety, pharmacokinetics and initial efficacy. The clinical trial will be carried out at various areas in the USA, including Sarah Cannon Research Institute in Nashville, Tennessee.

OMP-52M51 is a humanised monoclonal antibody that targets cancer stem cells. The company's preclinical results are very encouraging. Dr. Ian Flinn ,the scientist who treated the first cancer patient with OMP-52M51, said

“It is exciting to bring a novel antibody such as OMP- 52M51 that targets the Notch pathway, a key cancer stem cell pathway, into the clinic. There is significant scientific evidence to suggest that Notch1 could be an important therapeutic target in haematological malignancies, and we look forward to generating clinical data that might help patients with these cancers. The bio marker strategy employed in this study is also quite innovative.”

OncoMed is a biopharmaceutical company that focuses on the development of monoclonal antibodies that target cancer stem cells. As of now, the company has three anti-CSC product candidates in clinical development.

Cancer stem cells (CSCs), are cancer cells that have characteristics associated with regular stem cells, specifically the ability to renew themselves and the capacity to develop into cell types found in the originating cancer sample.

You can read the company's  press release here

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !